Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck & Co. Inc.

www.merck.com

Latest From Merck & Co. Inc.

Only Health-Care Case At US Supreme Court This Fall Looks At Preemption

The Supreme Court will hear arguments this fall in a lawsuit concerning whether FDA decisions can protect drug manufacturers from lawsuits filed under state failure-to-warn clauses. Device companies should also watch it, some attorneys say.

Medical Device Legal Issues

AbbVie Buys In On Morphic’s Oral Integrin Inhibitors, To Tune Of $100m

After years of industry unsuccessfully trying to find an oral version of the successful I.V. integrin inhibitors, Morphic has a prolific platform – and AbbVie is paying $100m up front for preclinical oral integrin inhibitors for fibrosis indications, potentially including NASH.

Deals Liver & Hepatic

Merck & Co.’s Keytruda/Inlyta Combo Invades Kidney Cancer Territory

Merck & Co.’s IO powerhouse Keytruda has trumped Bavencio’s recent Inlyta combo PFS win in kidney cancer, with a OS and PFS combo hit of its own. But the field is getting increasingly crowded. 

ImmunoOncology Clinical Trials

Medivir Clears The Decks For Clinical Focus, Cuts All Preclinical Projects

Medivir outlines plans to cut costs, reduce headcount and streamline priorities as the biotech focuses solely on four assets in clinical development.

Companies Commercial
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register